About The Study: This economic evaluation estimates that expanded Medicare coverage for glucagon-like peptide-1 receptor agonists (GLP-1RAs) would increase access and reduce obesity-related comorbidities but impose substantial costs over 10 years. Even with a moderate scenario (5% uptake, 20% adherence, and 30% additional price discount), net spending was still projected to reach $8 billion over a decade, underscoring the need for further price reductions, lower-cost strategies to prevent weight regain, and reductions in spending on low-value care.

Most people living in cities in Low- and Middle-Income Countries can reach primary care clinics within 30 minutes – yet average quality of care remains poor with clinicians failing to make correct diagnoses or implement appropriate treatments, new studies reveal.